Samsca is the brand name for the drug tolvaptan, a selective vasopressin v2 receptor antagonist. It is indicated for the treatment of hyponatremia resulting from conditions such as syndrome of inappropriate antidiuretic hormone secretion. The drug acts by blocking the binding of vasopressin to its v2 receptors in the kidney collecting ducts. This blockade prevents the normal antidiuretic effect of vasopressin, leading to increased water excretion through the urine. The resulting fluid loss raises serum sodium concentrations in patients with dilutional hyponatremia. Pharmacodynamically the medication increases urine volume without altering electrolyte levels other than sodium. Its therapeutic effect is achieved through selective antagonism of the v2 receptor, which modulates the activity of the aquaporin-2 water channels in renal cells.

Samsca is the brand name for tolvaptan a selective vasopressin receptor antagonist. It is prescribed to manage hyponatremia associated with conditions such as syndrome of inappropriate antidiuretic hormone secretion. The drug works by blocking the action of arginine vasopressin at v2 receptors in the collecting ducts. This blockade reduces water reabsorption and promotes the excretion of excess free water. The physiological effect is an increase in urine output and gradual normalization of serum sodium levels. By targeting only v2 receptors the medication achieves antidiuretic activity without significant impact on blood pressure. The therapeutic role of Samsca is to provide a pharmacologic means of correcting low sodium concentrations safely. Its pharmacological activity is confined to the vasopressin signaling pathway resulting in enhanced renal water clearance.

One possible side effect is increased thirst that some patients notice while taking the medication. Another is frequent urination, which may lead to dehydration if fluid intake is not managed. Some individuals experience dry mouth or a mild loss of appetite. Elevated liver enzyme levels have been reported in clinical studies, requiring periodic monitoring. Headache and dizziness can also occur, especially during the initial treatment phase. Fatigue is another symptom that has been observed in a minority of users. Lastly, low sodium levels may rebound after discontinuation, though this effect is generally temporary.

Patients may experience frequent urination as the drug promotes water excretion. Increased thirst often accompanies this effect. Some individuals report dry mouth or mild headaches. Liver function tests can show abnormalities in certain cases. Muscle cramps or weakness have been reported rarely. Fatigue or low energy levels may occur during treatment. Elevated uric acid levels have been observed in a small proportion of users. In rare instances, allergic skin reactions such as rash can develop.